SBIR/STTR Research Award

Optimizing correction of the Huntington's disease mutation by trans-splicing

Award identifier fd56d7e0367b7f1b0c6ee1ab7293ea7ba4ea8b43dc765146cc731a8726f0b1f2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$226,921

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
RETROTHERAPY, LLC
Proposal award date
2015-09-30
Contract end date
2016-09-29
UEI
Not reported
Solicitation number
PA14-071
Topic code
102

Research abstract

DESCRIPTION provided by applicant Recent studies by my laboratory and collaborators and by others have demonstrated that RNA trans splicing can correct mutations in many different genes in a wide range of disease model systems including Huntingtonandapos s disease Trans splicing is one of a handful of techniques that can convert the expression of a dominant negative mutation into the normal protein thus simultaneously reducing the cause of the disease and increasing the amount of a necessary protein Trans splicing is the only method that can achieve these results without the requirement for cell division We intend to develop optimal RNA trans splicing molecules RTMs to repair the CAG triplet repeat expansion in exon of the huntingtin gene which is the cause of Huntingtonandapos s disease Huntingtin targeted RTMs will be evaluated for their ability to efficiently and specifically trans splice and replace huntigtin exon at the RNA level by RT PCR at the protein level by Western blot and for their ability to minimize cellular toxicity in differentiated Huntingtonandapos s disease patient iPSC derived striatal neurons by nuclear condensation CellTiter Glo Cell Viability assay TUNEL assay and time lapse microscopy pre clinical candidate RTMs will be identified that most efficiently correct the expression of HTT with minimal toxicity for further development PUBLIC HEALTH RELEVANCE We intend to identify optimal therapeutic candidates to correct the causative mutation of Huntingtonandapos s disease by RNA trans splicing This could lead to the development of a treatment for patients with Huntingtonandapos s disease and ultimately for other genetic disorders

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.